drugset

drugset / Trial / NCT02388490

Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

NCT02388490 ↗

Phase 2 Completed 25 enrolled Seoul National University Hospital SMG-SNU Boramae Medical Center · collab Seoul National University Bundang Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin to evaluate ORR primarily in patients with EBV- and CD30-positive lymphomas.

Timeline

Start: 2016-03-25
Primary completion: 2019-04-02
Completion: 2019-04-02

Publications

Kim M, Lee JO, Koh J, Kim TM, Lee JY, Jeon YK, Keam B, Kim DW, Lee JS, Heo DS. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica. 2021 Aug 1;106(8):2277-2280. doi: 10.3324/haematol.2021.278301. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brentuximab Vedotin	Monoclonal antibody	1.8 mg/kg	Intravenous

Indications